Abstract
Until now, patients with platinum-resistant ovarian cancer have a poor prognosis with limited response to second-line single agent chemotherapy. Reported response rates are poor and encompasses 13-20%. Insufficient treatment efficacy reflects short survival. There is a need to investigate new combined chemotherapy regimens. The mechanism of action and the distinct toxicity profile of each agent are relevant variables in new regimen design . The appropriate pharmacological and toxicological properties of irinotecan and treosulfan allow us to evaluate the efficiency and safety of their combination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
